A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health indicates that out-of-pocket caps on insulin have successfully reduced prices for Medicare Part D beneficiaries across the United States. The study confirms significant cost declines following the implementation of the Inflation Reduction Act of 2022 mandates starting January one, 2023. This marks the first federal government imposition of price caps on insulin for all Medicare beneficiaries nationwide, signaling a major shift in health economics.
Researchers analyzed claims data covering nearly three point eight million patients who received at least one insulin prescription between 2019 and 2023 to determine the long-term effects. The percentage of patients paying 35 dollars or less monthly rose from 48% in 2019 to 75% in 2023 according to the comprehensive findings. Mean out-of-pocket costs for a 30-day supply fell from 50.87 dollars in 2019 to 21.98 dollars in 2023, representing a substantial reduction.
These decreases occurred across every United States state during the study window, demonstrating broad geographic effectiveness of the new policy framework. The Centers for Medicare & Medicaid Services previously capped costs at 35 dollars in 2021 through a limited voluntary initiative designed to test the market. The Inflation Reduction Act made this limit mandatory for Medicare Part D beneficiaries the following year to ensure consistent access.
Published online in JAMA on March 19, the peer-reviewed research letter represents the first analysis of the Inflation Reduction Act impact on insulin pricing specifically. The study focused on beneficiaries who did not receive Medicare low-income subsidies to ensure clear comparison of market rates without external aid. Data was grouped into five calendar years to track trends over the specific five-year period under review.
Michael Fang, PhD, assistant professor in the Bloomberg School Department of Epidemiology, stated the evidence shows policies improved access for seniors. He noted that insulin costs are now at historically low levels for people on Medicare compared to previous years. This validation suggests the federal government has achieved its intended goal for affordability and financial protection.
However, the researchers noted an unexpected finding regarding approximately 25% of beneficiaries who still paid more than 35 dollars in 2023. These individuals usually had at least one prescription that was not prorated to the Inflation Reduction Act limit due to plan administration. This suggests gaps remain in how plans apply the cost cap rules to specific prescription lengths.
Variations in average 30-day insulin costs by state ranged from 10.36 dollars in Washington, D.C. to 31.09 dollars in Minnesota during the final year. Fang explained that health plans can treat a 45-day supply the same as a 60-day supply and charge up to 70 dollars for the longer duration. Such prorating rules create inconsistencies in patient billing across different regions and insurance providers.
The research team is now exploring issues regarding prescriptions falling outside the current 60 and 90-day supply windows to find solutions. They aim to see in more detail how average costs vary across plans to identify systemic barriers for patients. Policy changes may be needed to close the remaining financial gap for patients relying on this essential medication.
Support for the research came from the National Institute of Diabetes and Digestive and Kidney Diseases through specific grant numbers K01DK138273 and R01DK139324. The study included co-authors Michael Fang, Chen Dun, Dan Wang, Caitlin Hicks, Elizabeth Selvin, Jung-Im Shin, and Mariana Socal from various institutions. This collaboration highlights the institutional effort to monitor healthcare economic shifts and policy outcomes.
Broader implications suggest that while the mandate works, administrative nuances require further scrutiny to ensure total equity for all stakeholders. Watch for CMS guidance updates on prorating as the agency continues to refine implementation of the cost cap regulations. Stakeholders will monitor whether future regulations address the remaining cost disparities to protect vulnerable populations.
